Phase 2 UNITY-NHL Study Regarding Umbralisib
Apr 15, 2021 ·
2m 31s
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.
Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.
Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.
Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.
Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.
Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.
Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.
Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Information
| Author | CheckRare Media |
| Organization | CheckRare |
| Website | - |
| Tags |
Copyright 2026 - Spreaker Inc. an iHeartMedia Company
Comments